Ophthalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502.

Abstract

Macroprolactinomas are pituitary tumours which have been effectively treated medically since the introduction of bromocriptine. The visual function of 13 patients treated with a new prolactin (PRL) inhibitor CV 205-502 (Sandoz Basle), a potent and selective dopamine D2 receptor agonist, was evaluated. This is the first detailed ophthalmic report of the use of this drug in macroprolactinomas. Patients were enrolled from June 1988 to July 1990 (mean follow up 30 months). Visual function including visual acuity, ocular pressure, and visual fields was regularly controlled. Visual fields (VF) were tested with Goldmann and automatic static perimetry (Vision Monitor). Treatment was globally effective. No modifications of the visual function were observed in nine patients (six normal, three previous VF losses after surgery). In four other patients, visual function dramatically improved (regression of a III paresis, one case; disappearance of a chiasmatic syndrome, three cases). A pituitary necrosis was observed in one case and successfully cured. CV 205-502 seems to be an effective and well tolerated treatment of macroprolactinomas.

• Authors: M Grochowicki, Y Khalfallah, A Vighetto, S Berquet, G Sassolas
• Journal: The British journal of ophthalmology (Br J Ophthalmol) Vol. 77 Issue 12 Pg. 785-8 (Dec 1993) ISSN: 0007-1161 [Print] England
• PMID: 7906538 (Publication Type: Journal Article)

Chemical References

• Aminoquinolines
• Dopamine Agents
• quinagolide
• Prolactin

Topics

• Adult
• Aminoquinolines (therapeutic use)
• Dopamine Agents (therapeutic use)
• Female
• Humans
• Intraocular Pressure (drug effects)
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Pituitary Neoplasms (drug therapy)
• Prolactin (antagonists & inhibitors)
• Prolactinoma (drug therapy)
• Vision, Ocular (physiology)
• Visual Acuity (drug effects)
• Visual Fields (drug effects)